Search

Corvus Pharmaceuticals Inc

Geschlossen

14.49 3.06

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.03

Max

15.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.4M

-14M

EPS

-0.15

Angestellte

37

EBITDA

312K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+112.08% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-29M

1.3B

Vorheriger Eröffnungskurs

11.43

Vorheriger Schlusskurs

14.49

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juli 2026, 23:56 UTC

AAR Corp shares are trading higher in after-market hours, reflecting typical fluctuations around the midpoint of their one-month range.

20. Juli 2026, 23:56 UTC

Nucor Corp shares are higher in after-market trading, reflecting routine performance. No specific news was identified to explain the price movement.

20. Juli 2026, 23:56 UTC

Epam Systems Inc. shares declined in after-market trading, aligning with a broader economic backdrop following a slight decrease in the Conference Board's leading economic index.

20. Juli 2026, 23:56 UTC

Definitive Healthcare Corp shares are lower in after-market hours, continuing a trend from recent sessions amid broader market uncertainties and weak economic data.

20. Juli 2026, 23:56 UTC

News

Brookdale Senior Living announced its second-quarter 2026 earnings release dates, boosting investor sentiment. Shares are trading higher in after-market hours.

20. Juli 2026, 23:56 UTC

Delek US Holdings Inc shares are higher in after-market hours, continuing a directional advance from earlier in the session. No specific news was identified.

20. Juli 2026, 23:56 UTC

Harley-Davidson Inc shares are higher in after-market trading, recovering from an earlier dip and positioning above the 20-day moving average.

20. Juli 2026, 23:56 UTC

News

Valero Energy Corp gains in after-market trading on strong earnings forecast, with projected EPS of $9.81 and revenue expectations of $35.95 billion.

20. Juli 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

20. Juli 2026, 23:56 UTC

Correlated Moves

Teradyne Inc shares are higher in after-market trading, recovering from earlier session lows, as the Nasdaq 100 Index also moves up.

20. Juli 2026, 23:56 UTC

NextDecade Corp. shows a slight uptick in after-market trading, remaining stable around the midpoint of its one-month trading range.

20. Juli 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

20. Juli 2026, 23:56 UTC

Marathon Petroleum shares are higher in after-market trading, maintaining strength above the 20-day moving average despite a decline in the leading economic index.

20. Juli 2026, 23:56 UTC

Salesforce Inc. shares remained roughly flat after market hours. The Conference Board reported a modest decline in its leading economic index for June.

20. Juli 2026, 23:56 UTC

Aurora Innovation Inc shares are lower in after-market hours, with no specific news identified. Broader economic concerns include a decline in the leading economic index.

20. Juli 2026, 23:51 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Emerging Markets ETF rises in after-market trading, supported by strong performances from Taiwan Semiconductor and HDFC Bank, despite remaining near recent lows.

20. Juli 2026, 23:51 UTC

Sabre Corp shares are lower in after-market hours, continuing a decline since Monday's close and remaining below their 20-day moving average.

20. Juli 2026, 23:51 UTC

Daktronics Inc shares are higher in after-market hours, reflecting strong momentum and trading near the upper end of their one-month range.

20. Juli 2026, 23:51 UTC

Reinsurance Group of America shares are higher in after-market hours, supported by a significant rise in the reinsurance sub-sector. The price is near its one-month high.

20. Juli 2026, 23:51 UTC

CenterPoint Energy Inc shares are higher in after-market trading, reflecting a steady upward movement since Monday's close amid rising Treasury yields and economic index concerns.

20. Juli 2026, 23:51 UTC

Geo Group Inc shares are lower in after-market hours, reflecting broader market concerns over rising Treasury yields and a decline in the leading economic index.

20. Juli 2026, 23:51 UTC

HealthStream Inc shares are lower in after-market trading. Broader market concerns include rising Treasury yields and a decline in the Conference Board's leading economic index.

20. Juli 2026, 23:51 UTC

CEVA Inc shares rose in after-market trading, recovering from earlier volatility and contrasting with four consecutive lower closes. The stock remains below its 20-day moving average.

20. Juli 2026, 23:51 UTC

News
Correlated Moves

Ally Financial shares are lower in after-market trading despite the board declaring a quarterly cash dividend of $0.30 per share.

20. Juli 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, with no specific news identified to explain the movement. Trading activity has been notably active.

20. Juli 2026, 23:51 UTC

Amkor Technology Inc shares are trading higher in after-market hours, despite no specific news and increased caution in the broader market.

20. Juli 2026, 23:51 UTC

Mexico's Upcoming Balance of Trade Data on July 27, 2026, Expected to Reflect Economic Health Amid Geopolitical Tensions and Investment Recovery Signals.

20. Juli 2026, 23:51 UTC

Australia's Full-Time Employment Change Report Set for July 23, 2026: Market Eyes Job Growth Amid Economic Uncertainty.

20. Juli 2026, 23:51 UTC

Australia's July 2026 employment change forecast predicts a modest increase of 15,000 jobs amid mixed labor market sentiment and potential impacts from skilled migration reforms.

20. Juli 2026, 23:51 UTC

Australia's unemployment rate for June 2026 is set to be released on July 23, with a forecast of 4.4%, amid cautious optimism in local markets despite global economic uncertainties.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

112.08% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD  112.08%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat